Wellbutrin is an effective option for managing depression, seasonal affective disorder, and supporting smoking cessation when used at the correct dose
Significant Limitations : High costs, access barriers, tolerability issues, and sustainability concerns prevent these agents from achieving their full transformative potential at a population level
Compounded drugs are not FDA-approved, so the FDA does not review the drugs safety, effectiveness, or quality before they are marketed
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite